Source: Annual Congress 2004 - Treatment of lung cancer and lung metastases
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
B. P. Van Putte, J. M. H. Hendriks, S. Romijn, B. Pauwels, J. B. Vermorken, P. E. Y. Van Schil (Edegem, Belgium). Combination chemotherapy with gemcitabine using isolated lung perfusion for the treatment of lung metastases. Eur Respir J 2004; 24: Suppl. 48, 388

Member's Comments

No comment yet.

Related content which might interest you: Carboplatin and paclitaxel chemotherapy for lung cancer patients with interstitial lung disease Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Toxicity in isolated lung perfusion with melphalan for resectable lung metastases Source: Annual Congress 2006 - Contemporary issues in thoracic surgical oncology Year: 2006 Initial combined intratumoral chemotherapy with cisplatin and irradiation for inoperable non-small cell obstructive lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 492s Year: 2004 Temozolomide in the treatment of brain metastases in lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003 Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial Source: Eur Respir J 2004; 24: Suppl. 48, 42s Year: 2004 Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Source: Eur Respir J 2006; 27: 1183-1189 Year: 2006 Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection? Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications Year: 2019 Treatment of limited disease-small cell lung cancer Source: Eur Respir Mon; 2009: 44: 299–309 Year: 2009 Locally advanced inoperable non-small cell lung cancer (NSCLC) treated by weekly paclitaxel/carboplatin chemotherapy with concomitant radiotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 433s Year: 2007 Docetaxel and carboplatin as the second-line treatment of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 464s Year: 2002 Resistance to chemotherapy in lung cancer Source: International Congress 2015 – Resistance to therapy in lung cancer Year: 2015 Adjuvant therapy in NSCLC Source: Annual Congress 2007 - Clinical year in review Year: 2007 Consolidation maintenance oral vinorelbine following concurrent chemoradiation of intravenous vinorelbine and cisplatin in patients with unresectable stage III non-small cell lung cancer Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015 Phase I/II study of biweekly docetaxel/cisplatin with concurrent thoracic radiotherapy for locally advanced non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Second-line weekly docetaxel in advanced non-small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Combination of neoadjuvant and adjuvant chemotherapy in marginally resectable IIIA nonsmall cell lung cancer (NSCLC): long-term follow up Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 Clinical characteristic of lung cancer patients with interstitial pneumonia treated with chemotherapy or radiotherapy Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005